Home ETF List About

Portfolio Holdings Detail for ISIN IE00B53SZB19
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / FundiShares NASDAQ 100 UCITS ETF USD (Acc)
IssuerBlackrock
ETF TickerCNX1(GBX) LSE
ETF TickerSXRV(EUR) F
ETF TickerCNDX.AS(EUR) CXE
ETF TickerCNDX.LS(USD) CXE
ETF TickerCNX1.LS(GBX) CXE
ETF TickerCSNDX.MI(EUR) CXE
ETF TickerCSNDXz(USD) CXE
ETF TickerSXRV.DE(EUR) CXE
ETF TickerCSNDX(EUR) ETF Plus
ETF TickerCNDX(EUR) Euronext Amsterdam
ETF TickerCNX1.L(GBP) LSE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares NASDAQ 100 UCITS ETF USD (Acc) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-30 (Tuesday)129,723REGN holding increased by 48USD 72,939,351REGN holding increased by 224095USD 72,939,35148USD 224,095 USD 562.27 USD 560.75
2025-09-29 (Monday)129,675REGN holding increased by 72USD 72,715,256REGN holding decreased by -367876USD 72,715,25672USD -367,876 USD 560.75 USD 563.9
2025-09-26 (Friday)129,603REGN holding increased by 36USD 73,083,132REGN holding increased by 1107368USD 73,083,13236USD 1,107,368 USD 563.9 USD 555.51
2025-09-25 (Thursday)129,567REGN holding increased by 36USD 71,975,764REGN holding decreased by -2761032USD 71,975,76436USD -2,761,032 USD 555.51 USD 576.98
2025-09-24 (Wednesday)129,531USD 74,736,796USD 74,736,796
2025-09-18 (Thursday)128,919REGN holding increased by 300USD 77,185,094REGN holding increased by 1878669USD 77,185,094300USD 1,878,669 USD 598.71 USD 585.5
2025-09-17 (Wednesday)128,619REGN holding increased by 372USD 75,306,425REGN holding increased by 1556705USD 75,306,425372USD 1,556,705 USD 585.5 USD 575.06
2025-09-16 (Tuesday)128,247REGN holding increased by 144USD 73,749,720REGN holding increased by 399223USD 73,749,720144USD 399,223 USD 575.06 USD 572.59
2025-09-15 (Monday)128,103USD 73,350,497USD 73,350,497
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00B53SZB19

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-30BUY48 562.270* 640.61
2025-09-29BUY72 560.750* 641.05
2025-09-26BUY36 563.900* 641.47
2025-09-25BUY36 555.510* 641.94
2025-09-18BUY300 598.710* 642.18
2025-09-17BUY372 585.500* 642.49
2025-09-16BUY144 575.060* 642.87
2025-09-11BUY96 568.200* 643.76
2025-08-29BUY144 580.700* 645.50
2025-08-22SELL-12 589.480* 645.83 Profit of 7,750 on sale
2025-08-21SELL-48 598.160* 646.11 Profit of 31,013 on sale
2025-08-20BUY36 591.010* 646.43
2025-08-19BUY120 571.780* 646.87
2025-08-15BUY360 580.410* 647.71
2025-08-13BUY288 561.550* 648.23
2025-08-12BUY48 556.555* 648.78
2025-08-05BUY84 569.900* 649.84
2025-08-04SELL-12 571.540* 650.32 Profit of 7,804 on sale
2025-07-31SELL-1,775 545.460* 651.55 Profit of 1,156,502 on sale
2025-07-30BUY96 554.580* 652.16
2025-07-28BUY96 558.630* 653.35
2025-07-17SELL-147 550.000* 654.60 Profit of 96,227 on sale
2025-07-15BUY49 547.960* 656.00
2025-07-14BUY49 570.590* 656.56
2025-07-11BUY49 567.740* 657.15
2025-07-09BUY98 552.580* 657.85
2025-07-08SELL-49 547.750* 658.58 Profit of 32,271 on sale
2025-07-02SELL-49 547.740* 661.71 Profit of 32,424 on sale
2025-07-01BUY294 534.910* 662.59
2025-06-26BUY294 521.000* 664.59
2025-06-25BUY484 520.290* 665.61
2025-06-24BUY98 522.270* 666.64
2025-06-18BUY96 513.580* 668.85
2025-06-17BUY49 508.860* 670.02
2025-06-16SELL-240 522.680* 671.11 Profit of 161,065 on sale
2025-06-13BUY49 529.240* 672.16
2025-06-12SELL-196 521.840* 673.28 Profit of 131,962 on sale
2025-06-06BUY49 493.220* 678.20
2025-06-05BUY96 483.070* 679.71
2025-06-04BUY98 484.930* 681.24
2025-06-03BUY1,176 487.860* 682.76
2025-06-02BUY49 490.810* 684.28
2025-05-30BUY194 490.280* 685.83
2025-05-29SELL-49 605.390* 686.48 Profit of 33,638 on sale
2025-05-28SELL-49 591.850* 687.25 Profit of 33,675 on sale
2025-05-23SELL-98 588.340* 689.60 Profit of 67,581 on sale
2025-05-22SELL-392 596.850* 690.38 Profit of 270,629 on sale
2025-05-20SELL-48 614.790* 691.76 Profit of 33,204 on sale
2025-05-19BUY96 596.540* 692.58
2025-05-16SELL-1,903 594.320* 693.43 Profit of 1,319,607 on sale
2025-05-15BUY441 584.990* 694.39
2025-05-14BUY98 571.360* 695.47
2025-05-13BUY441 574.160* 696.56
2025-05-12BUY343 575.630* 697.65
2025-05-08BUY147 547.670* 700.58
2025-05-02BUY98 605.610* 705.09
2025-04-29BUY196 568.910* 708.60
2025-04-28BUY343 610.860* 709.57
2025-04-25BUY147 602.640* 710.64
2025-04-24BUY98 599.760* 711.76
2025-04-23BUY98 587.850* 713.02
2025-04-22BUY343 585.490* 714.34
2025-04-16BUY98 549.280* 721.00
2025-04-15BUY245 557.910* 722.78
2025-04-14BUY588 571.060* 724.44
2025-04-11BUY200 554.180* 726.34
2025-04-09BUY550 576.720* 730.08
2025-04-08BUY1,000 556.810* 732.07
2025-04-04SELL-650 573.450* 735.81 Profit of 478,279 on sale
2025-04-02SELL-50 625.600* 737.13 Profit of 36,856 on sale
2025-04-01SELL-50 617.000* 738.57 Profit of 36,929 on sale
2025-03-31SELL-344 634.230* 739.85 Profit of 254,507 on sale
2025-03-26BUY444 640.140* 743.72
2025-03-25BUY547 634.140* 745.13
2025-03-24BUY150 661.000* 746.22
2025-03-21BUY50 658.480* 747.37
2025-03-20BUY100 662.620* 748.50
2025-03-19BUY391 672.360* 749.53
2025-03-18BUY100 664.960* 750.69
2025-03-17SELL-150 678.420* 751.69 Profit of 112,754 on sale
2025-03-14BUY250 666.870* 752.89
2025-03-13BUY100 680.610* 753.92
2025-03-11SELL-280 718.160* 755.39 Profit of 211,511 on sale
2025-03-10SELL-250 744.830* 755.55 Profit of 188,888 on sale
2025-03-06SELL-250 698.440* 757.17 Profit of 189,293 on sale
2025-03-05SELL-100 687.150* 758.26 Profit of 75,826 on sale
2025-03-04SELL-450 675.490* 759.58 Profit of 341,810 on sale
2025-03-03SELL-235 684.870* 760.78 Profit of 178,784 on sale
2025-02-28SELL-145 698.740* 761.80 Profit of 110,461 on sale
2025-02-25SELL-200 723.470* 764.42 Profit of 152,885 on sale
2025-02-20SELL-100 696.020* 767.76 Profit of 76,776 on sale
2025-02-19SELL-300 685.660* 769.28 Profit of 230,785 on sale
2025-02-18SELL-150 680.000* 770.97 Profit of 115,645 on sale
2025-02-13BUY100 674.270* 776.80
2025-02-07BUY100 710.000* 785.00
2025-01-29BUY200 687.270* 801.65
2025-01-28BUY50 686.330* 804.68
2025-01-27SELL-5 684.710* 807.92 Profit of 4,040 on sale
2025-01-24BUY150 675.790* 811.59
2025-01-23SELL-2,100 694.640* 814.94 Profit of 1,711,364 on sale
2025-01-22BUY145 680.030* 818.90
2024-12-10BUY49 778.500* 820.13
2024-12-09SELL-343 788.000* 821.13 Profit of 281,648 on sale
2024-12-06BUY196 778.000* 822.52
2024-12-05BUY49 767.900* 824.34
2024-12-03SELL-196 749.570* 829.52 Profit of 162,585 on sale
2024-12-02BUY98 762.340* 832.00
2024-11-29BUY144 750.220* 835.15
2024-11-27BUY98 754.870* 841.84
2024-11-26BUY49 753.030* 845.70
2024-11-22BUY150 738.000* 855.41
2024-11-21BUY49 744.500* 860.96
2024-11-19BUY147 744.600* 873.95
2024-11-18SELL-507 762.000* 880.54 Profit of 446,434 on sale
2024-11-12BUY196 821.000* 884.26
2024-11-08BUY49 828.420* 892.43
2024-11-07BUY1,225 824.480* 897.66
2024-11-06BUY147 816.650* 904.41
2024-11-05BUY49 829.430* 911.23
2024-11-04BUY98 828.840* 919.47
2024-10-25BUY98 933.020* 950.28
2024-10-24SELL-98 928.900* 957.41 Profit of 93,826 on sale
2024-10-21BUY147 968.500* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.